Ozmosi | Imipenem Drug Profile

Product Description

Imipenem is in a class of medications called carbapenem antibiotics. It works by killing bacteria. (Sourced from: https://medlineplus.gov/druginfo/meds/a686013.html)

Mechanisms of Action: PBP Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: *

Approval Status: Not Approved

Approved Indications: None

Known Adverse Events: None

Company: Merck
Company Location: Eastern America
Company Founding Year: 1668
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Imipenem

Countries in Clinic: China, France, Israel, Spain, United States

Active Clinical Trial Count: 7

Recent & Upcoming Milestones

Highest Development Phases

Phase 3: Communicable Diseases|Pneumonia, Bacterial|Pneumonia, Ventilator-Associated|Pyelonephritis|Urinary Tract Infections

Phase 2: Acute Respiratory Distress Syndrome|Febrile Neutropenia

Phase 1: Sepsis

Trial ID	Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success	Latest Trial Update Date	Data Updated
NCT06569056	HRS-8427-302	P3	Recruiting	Pyelonephritis\|Urinary Tract Infections\|Communicable Diseases	2025-11-01	20%	2024-10-12	Primary Endpoints\|Start Date\|Treatments\|Trial Status
NCT04983901	NCI-2021-01957	P2	Completed	Acute Respiratory Distress Syndrome\|Febrile Neutropenia	2023-10-06	12%	2024-03-13	Primary Endpoints
NCT04493151	NCT04493151	P1	Completed	Sepsis	2023-05-31	12%	2023-09-23	Primary Completion Date\|Primary Endpoints\|Study Completion Date\|Treatments\|Trial Status
NCT05204563	REITAB-2	P3	Completed	Pneumonia, Bacterial\|Pneumonia, Ventilator-Associated	2024-09-29	9%	2025-03-06	Primary Completion Date\|Primary Endpoints\|Study Completion Date\|Treatments\|Trial Status
CTR20244156	CTR20244156	P1	Completed	Urinary Tract Infections\|Pneumonia, Ventilator-Associated	2024-12-27		2025-04-29	Patient Enrollment\|Primary Completion Date\|Start Date\|Study Completion Date\|Treatments\|Trial Status
CTR20223300	CTR20223300	P3	Completed	Urinary Tract Infections	2023-10-29		2025-04-29	Patient Enrollment\|Primary Completion Date\|Start Date\|Study Completion Date\|Treatments\|Trial Status
2022-501952-27-00	XNW4107-302	P3	Completed	Pneumonia, Bacterial\|Pneumonia, Ventilator-Associated	2024-07-26		2025-05-02	Treatments

Recent News Events

Date	Type	Title
10/21/2025	News Article	PIVOT-PO Phase 3 Data Show Tebipenem HBr's Potential as the First Oral Carbapenem Antibiotic for Patients with Complicated Urinary Tract Infections (cUTIs)
10/14/2025	News Article	Spero Therapeutics Announces Presentations on Tebipenem Hbr at IDWeek
07/22/2025	News Article	Arch Biopartners Announces Start of Patient Recruitment in Phase II PONTIAK Trial Targeting Drug-Toxin-Related Acute Kidney Injury (AKI)
05/28/2025	News Article	Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions

Session Expiring Soon

Imipenem

Alternative Names: imipenem, recarbrio, primaxin, primaxin iv Clinical Status: Inactive Latest Update: 2025-12-11 Latest Update Note: Clinical Trial Update